Japan is no longer a market foreign medical device companies can afford to treat as “difficult […]
To all the healthcare innovation leaders, urban gerontologists, and care ecosystem designers in the world: if […]
The High Stakes of Innovation: Balancing Takeda’s $1.26B ‘Launch Machine’ and a $2.5B Antitrust Hit as […]
Is Shionogi going global as a pharmaceutical company from Japan, or simply buying growth while its […]
Japan wants biotechnology to become a larger part of its economy by 2030. That is the […]
Japan is one of the world’s most demanding healthcare markets. It is also one of the […]
Takeda’s savings programme is no longer an abstract investor slide. It has moved from corporate language […]
The JPY 200 billion savings target currently dominating Takeda’s internal dialogue isn’t just a number on […]